The development of chimeric antigen receptor (CAR) -based cell therapies is revolutionizing the treatment of human cancers and autoimmune diseases. As this innovative therapeutic modality continues to improve and become more accessible, better reagents are improving our ability to detect, identify, and fully characterize CAR-expressing cells. With a growing portfolio of innovative products, CST is helping to advance researchers’ work in this field.

Characterize Your CAR-Engineered Cells Easier and Faster
One of the most significant challenges facing scientists developing and characterizing CAR-engineered cells is the need for robust, sensitive, and selective research reagents for the identification of CAR-engineered cells. If you plan to use an immunoassay platform in your research, developing your own anti-idiotype antibodies to identify CAR-engineered cells can be a long and resource-intensive process.

To visit website, click here